Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease

PM Ridker, M Rane - Circulation research, 2021 - Am Heart Assoc
IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of
physiological functions traditionally associated with host defense, immune cell regulation …

Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines

A Fara, Z Mitrev, RA Rosalia, BM Assas - Open biology, 2020 - royalsocietypublishing.org
Coronavirus disease 2019 (COVID-19) has swept the world, unlike any other pandemic in
the last 50 years. Our understanding of the disease has evolved rapidly since the outbreak; …

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

SA Jones, BJ Jenkins - Nature reviews immunology, 2018 - nature.com
The IL-6 family of cytokines consists of IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM),
leukaemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) …

Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade

SC Jordan, J Choi, I Kim, G Wu, M Toyoda, B Shin… - …, 2017 - journals.lww.com
The success of kidney transplants is limited by the lack of robust improvements in long-term
survival. It is now recognized that alloimmune responses are responsible for the majority of …

Immunosuppressive medications

AC Wiseman - Clinical Journal of the American Society of …, 2016 - journals.lww.com
Immunosuppressive agents are commonly used in the nephrologist's practice in the
treatment of autoimmune and immune-mediated diseases and transplantation, and they are …

Role of macrophages and related cytokines in kidney disease

E Cantero-Navarro, S Rayego-Mateos… - Frontiers in …, 2021 - frontiersin.org
Inflammation is a key characteristic of kidney disease, but this immune response is two-
faced. In the acute phase of kidney injury, there is an activation of the immune cells to fight …

A phase I/II trial of the interleukin-6 receptor–specific humanized monoclonal (tocilizumab)+ intravenous immunoglobulin in difficult to desensitize patients

AA Vo, J Choi, I Kim, S Louie, K Cisneros… - …, 2015 - journals.lww.com
Background Current desensitization (DES) methods are not always effective. Thus, novel,
more effective approaches are desirable. Interleukin (IL)-6 is an attractive target as it …

[HTML][HTML] Adipose-derived stem cells protect skin flaps against ischemia/reperfusion injury via IL-6 expression

CM Pu, CW Liu, CJ Liang, YH Yen, SH Chen… - Journal of Investigative …, 2017 - Elsevier
Flap necrosis is the most frequent postoperative complication encountered in reconstructive
surgery. We elucidated whether adipose-derived stem cells (ADSCs) and their derivatives …

Fibrosis of peritoneal membrane as target of new therapies in peritoneal dialysis

V Masola, M Bonomini, S Borrelli, L Di Liberato… - International journal of …, 2022 - mdpi.com
Peritoneal dialysis (PD) is an efficient renal replacement therapy for patients with end-stage
renal disease. Even if it ensures an outcome equivalent to hemodialysis and a better quality …

T cells and autoimmune kidney disease

A Suarez-Fueyo, SJ Bradley, D Klatzmann… - Nature Reviews …, 2017 - nature.com
Glomerulonephritis is traditionally considered to result from the invasion of the kidney by
autoantibodies and immune complexes from the circulation or following their formation in …